The emitted dose of drug from a valved holding chamber using five pressurized metered dose inhalers.

Federica Di Berardino, Antonio Cesarani, Agostina Moles, Oreste Brenna

Abstract


Background. The dose available at the mouth from a pressurised metered-dose inhaler (pMDI) cannot stay the same if it is used with a valved holding chamber (VHC). A different aerosol drug delivery system is created when the pMDI is used with the VHC and therefore the dose delivered to the patients is no longer that released from the pMDI alone, but the one emitted by the new system. This study aims to verify the emitted dose of five pMDI drugs when used with a VHC.

Methods. The emitted dose was expressed as the amount of drug within the respirable fraction available at the end of the VHC, i.e. the drug output (measured by high performance liquid chromatography) multiplied by the percentage of FDF determined using a laser diffraction analyser.

Results. the emitted doses were drastically reduced in comparison with the nominal doses (Beclomethasone from 250 to 90.5 µg, Budesonide from 200 to 100 µg, Ciclesonide from 160 to 102 µg Fluticasone from 250 to 116 µg, Salbutamol from 100 to 54 µg).

Conclusions. When pMDIs are employed with a VHC, the emitted dose drastically changes; it is more or less halved. In order to facilitate prescription by the physician, both the nominal and the emitted doses should be reported in the VHC package.


Keywords


emitted dose, FPF, FPD, nominal dose, pMDI, VHC

Full Text:

PDF

References


Dubus JC, Dolovich M. Emitted doses of salbutamol pressurized metered-dose inhaler from five different plastic spacer devices. Fundamental & Clinical Pharmacology. 2000; 14: 219-224.

Newhouse MT. Asthma therapy with aerosols: are nebulizers obsolete? A continuing controversy. J Pediatr. 1999; 135: 5-8.

Di Berardino L, Varricchio A, Teti L. Two basic parameters to standardize the delivery of aerosolized drugs. Respir Drug Deliv. 2004; IX: 545-48.

Malone RA, Hollie MC, Glynn-Barnhart A, Nelson HS. Optimal duration of nebulized albuterol therapy. Chest. 1993 Oct;104(4):1114-8.

Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest.1994; 106: 1788-92.

Crim C, Holmes M, Lee B, Cavanaugh R, Lincourt W.Evaluation of particle size distribution of albuterol sulfate hydrofluoroalkane administered via metered-dose inhaler with and without valved holding chambers.Ann Allergy Asthma Immunol. 2005 Jan;94(1):80-5.

Kelly HW, Ahrens RC, Holmes M, Stevens AL, Vandermeer AK, Garris T, Reisner C Evaluation of particle size distribution of salmeterol administered via metered-dose inhaler with and without valved holding chambers. Ann Allergy Asthma Immunol. 2001 Dec;87(6):482-7.

Chambers F, Ludzik A. In vitro drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler. J Aerosol Med Pulm Drug Deliv. 2009 Jun;22(2):113-20.

Schultz A, Le Souëf TJ, Looi K, Zhang G, Le Souëf PN, Devadason SG. Validation of methodology for recording breathing and simulating drug delivery through spacers and valved holding chambers. J Aerosol Med Pulm Drug Deliv. 2010; 23: 311-22

Newman SP, Clarke SW. Therapeutic aerosols 1--physical and practical considerations. Thorax.1983; 38: 881-6.

Di Berardino L, Scarione SF. Mixing albuterol and corticosteroid is not additive. Allergy 1999; 54: 1004-13.

Steckel H, Muller BW. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. Int J Pharm. 1997; 154:19-29.

Singh D, Collarini S, Poli G, Acerbi D, Amadasi A, Rusca A. Effect of AeroChamber Plus(TM) on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. Br J Clin Pharmacol. 2011 May 25. doi: 10.1111/j 1365-2125.2011.04024.x.

Nair A, McKinlay L, Williamson P, Short P, Burns P, Lipworth BJ. Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. Eur J Clin Pharmacol. 2011 Apr;67(4):355-63. Epub 2011 Jan 15.

Asmus MJ, Liang J, Coowanitwong I, Hochhaus G. In vitro performance characteristics of valved holding chamber and spacer devices with a fluticasone metered-dose inhaler. Pharmacotherapy. 2004 Feb;24(2):159-66.

Salyer JW, DiBlasi RM, Crotwell DN, Cowan CA, Carter ER.The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience. Respir Care. 2008 Mar;53(3):338-45.

Janssens HM, Krijgsman A, Verbraak TF, Hop WC, de Jongste JC, Tiddens HA. Determining factors of aerosol deposition for four pMDI-spacer combinations in an infant upper airway model. J Aerosol Med. 2004 Spring;17(1):51-61.

Louca E, Leung K, Coates AL, Mitchell JP, Nagel MW.Comparison of three valved holding chambers for the delivery of fluticasonepropionate-HFA to an infant face model.J Aerosol Med. 2006;19:160-7.

Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011 Jun;37(6):1308-31.

EMEA/CHMP/QWP/49313/2005. London, 21 June 2006.

Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J. 2007 Aug;16(4):207-14. Review.


Refbacks

  • There are currently no refbacks.




Copyright (c)

               AR Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India

Copyright@arjournals.org (Design) 2009-2021

 

Follow @arjournals on Twitter